NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational ...

Don't Miss our Black Friday Offers: Debanjana Chatterjee’s rating is based on several positive factors surrounding Intellia Therapeutics’ nex-z treatment for ATTR-CM. The assessment includes insights ...

Intellia Therapeutics, Inc. (NTLA), a clinical-stage gene editing company, Monday said that the U.S. Food and Drug Administration or ...

Shares of biotech Intellia Therapeutics ( NTLA 5.18%) are down by around 33% over the past 30 days, amid the publication of ...

Nex-z是一款基于Intellia公司专有的非病毒平台，利用脂质纳米颗粒（LNP）向肝脏输送由两部分组成的体内CRISPR/Cas9基因编辑系统：靶向TTR基因的特异性引导RNA（gRNA）和编码Cas9酶的mRNA。通过体内失活TTR基因，nex ...

Penny stocks are shares of smaller or newer companies, often in their early stages of development. These companies, however, ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement. Intellia Therapeutics has unveiled promising Phase 1 clinical ...